PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1892750
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1892750
Extracorporeal Membrane Oxygenation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
The Global Extracorporeal Membrane Oxygenation Market was valued at USD 475.5 million in 2025 and is estimated to grow at a CAGR of 4.5% to reach USD 721.6 million by 2035.
Market growth is driven by the rising prevalence of cardiopulmonary diseases and respiratory failures, rapid technological advancements in ECMO systems, and increasing awareness among patients regarding the benefits of these life-support devices. ECMO systems temporarily take over the function of the heart and lungs by circulating blood outside the body through an artificial membrane, adding oxygen and removing carbon dioxide. These devices are crucial in critical care when conventional therapies, such as mechanical ventilation, are insufficient, offering support during recovery or while awaiting organ transplantation. Enhanced healthcare literacy and government initiatives worldwide are encouraging adoption, while improved access to advanced treatment options ensures that ECMO is recognized as a vital intervention for severe cardiac and respiratory failures.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $475.5 Million |
| Forecast Value | $721.6 Million |
| CAGR | 4.5% |
The venoarterial (VA) ECMO segment accounted for a 45.7% share in 2025. VA ECMO delivers cardiopulmonary support for patients with severe cardiac failure, often combined with respiratory compromise, and is widely used for conditions such as cardiogenic shock, cardiac arrest, or as a bridge to heart transplantation. Its growing adoption is driven by proven effectiveness in critical cardiac conditions, including post-surgical complications and severe myocardial dysfunction.
The adult segment captured a 40.2% share in 2025, reflecting the higher prevalence of severe cardiac and respiratory conditions among adults due to lifestyle-related risk factors. ECMO adoption is increasing in tertiary hospitals as a preferred advanced critical care solution, providing life-saving support during high-risk surgeries or as a bridge to transplantation.
North America Extracorporeal Membrane Oxygenation Market held a 58.2% share in 2025. Growth in the region is fueled by advanced healthcare infrastructure, rising cardiopulmonary disease incidence, and continuous technological innovation, with cardiovascular disease burden further accelerating adoption.
Key players in the Global Extracorporeal Membrane Oxygenation Market include Abbott Laboratories, Getinge AB, Fresenius Medical Care AG & Co. KGaA, Medtronic, Eurosets, LivaNova PLC, Abiomed, Braile Biomedica, Hemovent GmbH, MicroPort Scientific Corporation, Nipro, Edwards Lifesciences Corporation, SB-Kawasumi Laboratories, Inc., and Senko Medical Instrument Mfg. Co., Ltd., Spectrum Medical, Terumo Corporation, and Weigao Group Co., Ltd. Companies in the Extracorporeal Membrane Oxygenation Market strengthen their presence by investing heavily in R&D to develop innovative, energy-efficient, and compact ECMO systems with improved safety features. Expanding global distribution networks ensures timely delivery and service support for hospitals and critical care centers. Strategic partnerships with healthcare providers and government agencies enable long-term adoption contracts and market penetration. Manufacturers focus on enhancing product usability, reducing complications, and providing training programs for medical staff to improve device acceptance.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Modality trends
- 2.2.3 Application trends
- 2.2.4 Patient population trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increase in cases of cardiopulmonary diseases and respiratory failures
- 3.2.1.2 Technological advancements in ECMO devices
- 3.2.1.3 Rising patient awareness about benefits delivered by extracorporeal membrane oxygenation devices
- 3.2.1.4 Rising government initiatives and programs worldwide
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of equipment
- 3.2.2.2 Dearth of skilled professionals
- 3.2.2.3 Risks related to ECMO device
- 3.2.3 Market opportunities
- 3.2.3.1 Home-based and long-term ECMO solutions
- 3.2.3.2 Integration with artificial intelligence and digital monitoring
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological advancements
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Supply chain analysis
- 3.7 Reimbursement scenario
- 3.8 Pricing analysis, 2025
- 3.9 Future market trends
- 3.10 Gap analysis
- 3.11 Porter's analysis
- 3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2025
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Mergers and acquisitions
- 4.6.2 Partnerships and collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Modality, 2022 - 2035 ($ Mn)
- 5.1 Key trends
- 5.2 Venoarterial (VA)
- 5.3 Veno-venous (VV)
- 5.4 Arteriovenous (AV)
Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)
- 6.1 Key trends
- 6.2 Cardiac diseases
- 6.3 Respiratory diseases
- 6.4 Extracorporeal cardiopulmonary resuscitation (ECPR)
Chapter 7 Market Estimates and Forecast, By Patient Population, 2022 - 2035 ($ Mn)
- 7.1 Key trends
- 7.2 Infant
- 7.3 Pediatric
- 7.4 Adult
Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 Abiomed
- 9.3 Eurosets
- 9.4 Braile Biomedica
- 9.5 Edwards Lifesciences Corporation
- 9.6 Fresenius Medical Care AG & Co. KGaA
- 9.7 Getinge AB
- 9.8 Hemovent GmbH
- 9.9 LivaNova PLC
- 9.10 Medtronic
- 9.11 MicroPort Scientific Corporation
- 9.12 Nipro
- 9.13 SB-Kawasumi Laboratories, Inc.
- 9.14 Senko Medical Instrument Mfg. Co., Ltd.
- 9.15 Spectrum Medical, Terumo Corporation
- 9.16 Weigao Group Co., Ltd.
